FR20C1038I2 - Derives de benzamidazole - Google Patents

Derives de benzamidazole

Info

Publication number
FR20C1038I2
FR20C1038I2 FR20C1038C FR20C1038C FR20C1038I2 FR 20C1038 I2 FR20C1038 I2 FR 20C1038I2 FR 20C1038 C FR20C1038 C FR 20C1038C FR 20C1038 C FR20C1038 C FR 20C1038C FR 20C1038 I2 FR20C1038 I2 FR 20C1038I2
Authority
FR
France
Prior art keywords
benzamidazole
derivatives
benzamidazole derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1038C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of FR20C1038I1 publication Critical patent/FR20C1038I1/fr
Application granted granted Critical
Publication of FR20C1038I2 publication Critical patent/FR20C1038I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR20C1038C 2007-06-29 2020-08-20 Derives de benzamidazole Active FR20C1038I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02
PCT/IB2008/001575 WO2009004427A2 (fr) 2007-06-29 2008-06-16 Dérivés de benzamidazole

Publications (2)

Publication Number Publication Date
FR20C1038I1 FR20C1038I1 (fr) 2020-10-02
FR20C1038I2 true FR20C1038I2 (fr) 2021-08-13

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1038C Active FR20C1038I2 (fr) 2007-06-29 2020-08-20 Derives de benzamidazole

Country Status (46)

Country Link
US (2) US8148401B2 (fr)
EP (1) EP2170860B9 (fr)
JP (2) JP4567099B2 (fr)
KR (1) KR101143246B1 (fr)
CN (1) CN101687841B (fr)
AP (1) AP2377A (fr)
AR (1) AR067346A1 (fr)
AU (1) AU2008272641B2 (fr)
BR (1) BRPI0813412B8 (fr)
CA (1) CA2690953C (fr)
CL (1) CL2008001922A1 (fr)
CO (1) CO6160232A2 (fr)
CR (1) CR11150A (fr)
CU (1) CU23847B1 (fr)
CY (2) CY1118650T1 (fr)
DK (1) DK2170860T5 (fr)
DO (1) DOP2009000278A (fr)
EA (1) EA016888B1 (fr)
EC (1) ECSP099803A (fr)
ES (1) ES2609258T3 (fr)
FR (1) FR20C1038I2 (fr)
GE (1) GEP20125702B (fr)
GT (1) GT200900328A (fr)
HK (1) HK1139658A1 (fr)
HN (1) HN2008000974A (fr)
HR (1) HRP20161562T2 (fr)
HU (2) HUE030052T4 (fr)
IL (1) IL202420A (fr)
LT (2) LT2170860T (fr)
MA (1) MA31466B1 (fr)
ME (1) ME00962B (fr)
MY (1) MY148636A (fr)
NI (1) NI200900219A (fr)
NL (1) NL301057I2 (fr)
NO (1) NO2020027I1 (fr)
NZ (1) NZ581889A (fr)
PA (1) PA8785401A1 (fr)
PE (2) PE20090772A1 (fr)
PL (1) PL2170860T3 (fr)
PT (1) PT2170860T (fr)
RS (1) RS55395B9 (fr)
SI (1) SI2170860T1 (fr)
TN (1) TN2009000544A1 (fr)
TW (1) TWI371451B (fr)
UY (1) UY31164A1 (fr)
WO (1) WO2009004427A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581889A (en) 2007-06-29 2011-05-27 Pfizer Benzimidazole derivatives
WO2010028192A1 (fr) 2008-09-03 2010-03-11 Repligen Corporation Compositions comprenant des dérivés d’acide 6-aminohexanoïque utilisées comme inhibiteurs de hdac
AU2010257802A1 (en) * 2009-06-11 2012-01-12 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
KR20120078703A (ko) 2009-08-26 2012-07-10 다케다 야쿠힌 고교 가부시키가이샤 융합 헤테로시클릭 고리 유도체 및 이의 용도
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
WO2012052948A1 (fr) 2010-10-20 2012-04-26 Pfizer Inc. Dérivés de pyridine-2 en tant que modulateurs des récepteurs smoothened
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Ｎｔｔドコモ ホーム基地局及びハンドオーバ方法
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP3524324A1 (fr) 2011-02-28 2019-08-14 BioMarin Pharmaceutical Inc. Inhibiteurs de l'histone désacétylase
US9051305B2 (en) 2011-03-08 2015-06-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
US9527850B2 (en) 2011-09-26 2016-12-27 Merck Patent Gmbh Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist
US20150133450A1 (en) 2012-06-20 2015-05-14 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2014081953A1 (fr) 2012-11-21 2014-05-30 Richard David J Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 et des dérivés d'isoquinoléine et de quinoléine
JP6503338B2 (ja) 2013-03-15 2019-04-17 バイオマリン ファーマシューティカル インコーポレイテッド Ｈｄａｃ阻害剤
WO2014170350A1 (fr) * 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Composés destinés à être utilisés comme inhibiteurs de bromodomaine
WO2015017788A1 (fr) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Méthode permettant de prédire la sensibilité d'un cancer
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
WO2015066305A1 (fr) 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Procédés de détermination de la chimiosensibilité et de la chimiotoxicité
HUE048664T2 (hu) * 2015-04-24 2020-07-28 Pfizer 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-il)-l-metilpiperidin-4-il)-3-(4-cianofenil)-karbamid-maleát kristályformái
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2020164722A (ja) * 2019-03-29 2020-10-08 デクセリアルズ株式会社 接着剤組成物
US20230107634A1 (en) 2020-01-28 2023-04-06 Teva Pharmaceuticals International Gmbh Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
WO2021191278A1 (fr) 2020-03-26 2021-09-30 Lek Pharmaceuticals D.D. Forme dimaléate de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-méthylpipéridine -4-yl)-3-(4-cyanophényl)urée
KR20230031285A (ko) 2020-06-26 2023-03-07 라퀄리아 파마 인코포레이티드 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약
WO2023002362A1 (fr) 2021-07-22 2023-01-26 Pfizer Inc. Traitement d'une malignité hématologique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040031782A (ko) * 2001-07-27 2004-04-13 쿠리스 인코퍼레이션 헤지호그 신호전달 경로의 조절물질, 이를 함유하는조성물 및 이의 용도
IL162851A0 (en) * 2001-12-04 2005-11-20 Actelion Pharmaceuticals Ltd 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
MXPA05003948A (es) * 2002-10-17 2005-06-17 Amgen Inc Derivados de bencimidazol y su uso como ligandos de receptor vaniloide.
WO2005042495A1 (fr) 2003-10-21 2005-05-12 Imclone Systems Incorporated Composes de (benzimidazol-2-yl)-phenyl-phenyl-uree et procedes d'inhibition de l'activite de l'heparanase
WO2005042497A2 (fr) 2003-10-28 2005-05-12 Vertex Pharmaceuticals, Incorporated Benzimidazoles convenant comme modulateurs des canaux ioniques
JP2008519044A (ja) 2004-11-03 2008-06-05 キューリス，インコーポレーテッド ヘッジホッグ・シグナル伝達経路の伝達物質、調合物、及び、それに関連する使用
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (fr) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
WO2008064830A1 (fr) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, leurs procédés de fabrication et leurs utilisations pharmaceutiques
EP2121626A1 (fr) 2006-12-15 2009-11-25 Pfizer Products Inc. Dérivés du benzamidazole
NZ581889A (en) 2007-06-29 2011-05-27 Pfizer Benzimidazole derivatives
WO2009154739A2 (fr) 2008-06-17 2009-12-23 Duke University Modulateurs du récepteur smoothened
CA2733533C (fr) 2008-08-25 2013-12-17 Irm Llc Modulateurs de la voie hedgehog

Also Published As

Publication number Publication date
DK2170860T3 (en) 2017-01-09
PA8785401A1 (es) 2009-01-23
CN101687841A (zh) 2010-03-31
BRPI0813412B8 (pt) 2021-05-25
GEP20125702B (en) 2012-12-10
RS55395B9 (sr) 2020-01-31
TW200911792A (en) 2009-03-16
DOP2009000278A (es) 2009-12-31
EP2170860A2 (fr) 2010-04-07
HRP20161562T1 (hr) 2016-12-30
AR067346A1 (es) 2009-10-07
EA200971104A1 (ru) 2010-06-30
HUE030052T2 (hu) 2017-04-28
NL301057I2 (nl) 2020-09-10
CY2020028I2 (el) 2020-11-25
JP4567099B2 (ja) 2010-10-20
KR20100028120A (ko) 2010-03-11
CA2690953A1 (fr) 2009-01-08
CO6160232A2 (es) 2010-05-20
EP2170860B1 (fr) 2016-11-02
JP2010531869A (ja) 2010-09-30
FR20C1038I1 (fr) 2020-10-02
US8148401B2 (en) 2012-04-03
EP2170860B9 (fr) 2017-02-22
HRP20161562T2 (hr) 2017-04-21
CA2690953C (fr) 2012-10-02
CN101687841B (zh) 2013-07-10
EA016888B1 (ru) 2012-08-30
MA31466B1 (fr) 2010-06-01
CY1118650T1 (el) 2017-07-12
HUE030052T4 (en) 2017-06-28
PL2170860T3 (pl) 2017-05-31
CU20090225A7 (es) 2012-02-15
GT200900328A (es) 2011-08-29
HUS2000031I1 (hu) 2020-09-28
US20120157495A1 (en) 2012-06-21
UY31164A1 (es) 2009-01-30
PE20121010A1 (es) 2012-08-06
WO2009004427A2 (fr) 2009-01-08
TWI371451B (en) 2012-09-01
CR11150A (es) 2010-02-08
AU2008272641B2 (en) 2013-08-29
SI2170860T1 (sl) 2017-01-31
NL301057I1 (nl) 2020-07-22
BRPI0813412A2 (pt) 2014-12-30
CU23847B1 (es) 2012-10-15
IL202420A (en) 2014-05-28
KR101143246B1 (ko) 2012-05-18
ECSP099803A (es) 2010-01-29
CY2020028I1 (el) 2020-11-25
AU2008272641A1 (en) 2009-01-08
NO2020027I1 (no) 2020-08-11
MY148636A (en) 2013-05-15
ME00962B (fr) 2012-06-20
LTPA2020528I1 (lt) 2020-09-25
CL2008001922A1 (es) 2009-01-02
WO2009004427A3 (fr) 2009-06-04
DK2170860T5 (en) 2017-03-20
ES2609258T3 (es) 2017-04-19
RS55395B1 (sr) 2017-04-28
US20090005416A1 (en) 2009-01-01
LTC2170860I2 (lt) 2022-03-10
IL202420A0 (en) 2010-06-30
AP2009005089A0 (en) 2009-12-31
AP2377A (en) 2012-03-07
NZ581889A (en) 2011-05-27
TN2009000544A1 (fr) 2011-03-31
BRPI0813412B1 (pt) 2020-01-21
JP2010280693A (ja) 2010-12-16
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
PT2170860T (pt) 2017-01-04
US8431597B2 (en) 2013-04-30
LT2170860T (lt) 2017-01-10
HN2008000974A (es) 2011-01-24
HK1139658A1 (en) 2010-09-24

Similar Documents

Publication Publication Date Title
FR20C1038I2 (fr) Derives de benzamidazole
FR22C1024I2 (fr) Derives de pyridazinone
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
BRPI0817935A2 (pt) Derivados de biarila
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0812518A2 (pt) Derivados de indazolamida
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
BRPI0810202A2 (pt) Derivados de piridina
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0915064A2 (pt) derivados de qunoxalinadiona
DK2152370T3 (da) Aryletherpyridazinonderivater
FR2902426B1 (fr) Derives de cinnamoyl-piperazine
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
DK2190837T3 (da) 4-pyrimidinsulfamid-derivat
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
BRPI0814718A2 (pt) Derivados de isoxazol-imidazol